The effect of Loratadine and Naproxen on prevention of pain caused by Granulocyte colony stimulating factor in cancer patients

Phase 3

• Conditions: Condition 1: Breast cancer. Condition 2: Multiple myeloma. Condition 3: Hodgkin lymphoma. Condition 4: Follicular lymphoma. Condition 5: Non-follicular lymphoma. Condition 6: Ovarian cancer. Condition 7: Vaginal cancer. Condition 8: Bladder cancer.; Malignant neoplasm of breast; Multiple myeloma and malignant plasma cell neoplasms; Hodgkin lymphoma; Follicular lymphoma; Non-follicular lymphoma; Malignant neoplasm of ovary; Malignant neoplasm of vagina; Malignant neoplasm of bladder

• Registration Number: IRCT20190922044848N1
• Lead Sponsor: Karaj University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients who are 18 years of age or older
Patients with malignancy confirmed by pathological reports
Patients receiving chemotherapy drugs and Granulocyte colony stimulating factor

Exclusion Criteria

Patients with a history of chronic pain
Patients with a history of gastrointestinal bleeding or ulcers
Patients who have a history of intolerance or hypersensitivity to antihistamines

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain severity due to Granulocyte colony stimulating factor. Timepoint: Measurement of pain severity 9 days after receiving Granulocyte colony stimulating factor. Method of measurement: McGill pain questionnaire.